Itp refractory to steroids

The risk of TEEs has been found to be increased in patients with chronic liver disease (CLD) treated with 75 mg eltrombopag once daily for two weeks in preparation for invasive procedures. Six of 143 (4%) adult patients with CLD receiving eltrombopag experienced TEEs (all of the portal venous system) and two of 145 (1%) subjects in the placebo group experienced TEEs (one in the portal venous system and one myocardial infarction). Five of the 6 patients treated with eltrombopag experienced the thrombotic complication at a platelet count > 200,000/µl and within 30 days of the last dose of eltrombopag. Eltrombopag is not indicated for the treatment of thrombocytopenia in patients with chronic liver disease in preparation for invasive procedures.

Physicians who express an interest in initiating self-administration of Nplate (romiplostim) for specific patients are provided with a Home Administration Training pack for those patients. The HAT pack includes materials for HCPs on how to select and train patients for self-administration of romiplostim; and for patients, in order to help them with the process of preparation and self-administration of the correct dose of romiplostim.
To request a copy of this material, please contact Amgen Medical Information on +44 (0) 1223 436441

Itp refractory to steroids

itp refractory to steroids

Media:

itp refractory to steroidsitp refractory to steroidsitp refractory to steroidsitp refractory to steroidsitp refractory to steroids

http://buy-steroids.org